Eiko Lifescience (540204)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 59.95% and profit growth of 195.12% show strong near-term momentum.
• P/E of 18.31 is not unreasonable for a company with high growth, and PEG of 0.14 suggests apparent cheapness.
• Piotroski F-Score of 6/9 indicates moderately sound financial fundamentals.
• P/B of 1.75 against book value of ₹36.50 is not excessive for a growth-oriented small cap.

Concerns

• ROE of 6.56% and ROCE of 0.00% imply poor capital productivity despite headline growth.
• No dividend means shareholders receive no return unless the share price keeps rising.
• Promoter holding and debt/equity data are not available, creating a serious transparency gap.
• Latest quarterly sales of ₹12 crore with net profit of ₹1 crore show thin absolute margins and small scale.

AI Analysis

At first glance, Eiko Lifescience looks like a fast-growing small-cap specialty chemical play. Sales up nearly 60% and profits up 195% sound wonderful, but I've learned to ask what the underlying return on capital is. Here ROE is just 6.56%, and ROCE is reported at 0.00%—that is a red flag, not a sign of a franchise. If the company is generating strong growth but barely earning on equity, much of the profit may be illusion from a low base or one-off factors. The P/E of 18.31 for a company with this growth appears cheap, and the PEG of 0.14 is striking, but I shouldn't trust a PEG when the quality of earnings is unclear. Latest quarter sales of ₹12 crore and net profit of ₹1 crore suggest a small absolute scale. Market cap of ₹85 crore means this is a microcap. There is no dividend; the book value is ₹36.50 against a price of ₹63.96, so P/B is 1.75—not excessive, but not a margin of safety. F-Score of 6/9 suggests reasonable financial health, but I cannot assess debt-equity or promoter holding, and that ignorance itself is concerning. In Graham's language, price is what you pay, value is what you get. Without a clear moat, without consistent high ROE, and without full ownership clarity, I would need a much lower price or much stronger balance-sheet evidence to consider it a true investment. Growth is wonderful, but only when it is backed by durable competitive advantage and honest, transparent numbers. Right now, this is a fast grower, not a stalwart. I'd watch it, but I would not buy it on these figures alone.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer